(Q33555591)

28 July 2017

title

Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy (English)

1 reference

28 July 2017

1 reference

Serena Di Cosimo

1

0 references

publication date

18 December 2009

1 reference

28 July 2017

published in

Breast Cancer Research

1 reference

28 July 2017

volume

11 Suppl 3

1 reference

28 July 2017

page(s)

S25

1 reference

Status of PI3K inhibition and biomarker development in cancer therapeutics

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2797705

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2797705

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2797705

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2797705

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2797705

TOR, a central controller of cell growth

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2797705

Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2797705

Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2797705

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FBCR2444

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FBCR2444

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FBCR2444

21 January 2018

Identifiers

DOI

10.1186/BCR2444

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference